Navigation Links
Liposarcoma -Pipeline Insights, 2014
Date:9/3/2014

NEW YORK, Sept. 3, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Liposarcoma -Pipeline Insights, 2014

http://www.reportlinker.com/p02278625/-Liposarcoma--Pipeline-Insights-2014.html

SUMMARY
DelveInsight's," Liposarcoma -Pipeline Insights, 2014", report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Liposarcoma . This report provides information on the therapeutic development based on the Liposarcoma dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.
Data Sources

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

Note*: This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated Indication.

Scope
- The report provides a snapshot of the global therapeutic landscape of Liposarcoma
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Liposarcoma pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Liposarcoma and also provide company profiling
- The report also gives the information of dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type


Reasons to buy
- Complete Pipeline intelligence and complete understanding over therapeutics development for Liposarcoma
- Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
- Devise corrective measures for pipeline projects by understanding Liposarcoma pipeline depth and focus of Indication therapeutics
- Developing strategic initiatives to support your drug development activities.
- Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
- Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
- Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions
Table of Contents
- Liposarcoma Overview
- Liposarcoma Pipeline Therapeutics
- Liposarcoma Therapeutics under Development by Companies
- Liposarcoma Late Stage Products (Filed and Phase III)
- Comparative Analysis
- Liposarcoma Mid Clinical Stage Products (Phase II)
- Comparative Analysis
- Liposarcoma Early Clinical Stage Products (Phase I and IND Filed)
- Comparative Analysis
- Liposarcoma Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- Liposarcoma – Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Liposarcoma – Discontinued Products
- Liposarcoma – Dormant Products
- Companies Involved in Therapeutics Development for Liposarcoma
- Appendix
- Methodology
- Contact Us
- Disclaimer

List of Tables

- Number of Products under Development for Liposarcoma , 2014
- Number of Products under Development by Companies
- Comparative Analysis by Late Clinical Stage Products (Filed and Phase III), 2014
- Comparative Analysis Mid Clinical Stage Products (Phase II), 2014
- Comparative Analysis Early Clinical Stage Products (Phase I and IND Filed), 2014
- Comparative Analysis Discovery and Pre-Clinical Stage Products, 2014
- Drug Candidates Profiles
- Liposarcoma Assessment by Monotherapy Products
- Liposarcoma Assessment by Combination Products
- Liposarcoma Assessment by Route of Administration
- Liposarcoma Assessment by Stage and Route of Administration
- Liposarcoma Assessment by Molecule Type
- Liposarcoma Assessment by Stage and Molecule Type
- Liposarcoma Therapeutics – Discontinued Products
- Liposarcoma Therapeutics – Dormant Products
- Products under Development by Companies, 2014

List of Figures

- Number of Products under Development for Liposarcoma , 2014
- Late Clinical Stage Products (Filed and Phase III), 2014
- Mid Clinical Stage Products (Phase II), 2014
- Early Clinical Stage Products (Phase I and IND Filed), 2014
- Discovery and Pre-Clinical Stage Products, 2014
- Liposarcoma Assessment by Monotherapy Products
- Liposarcoma Assessment by Combination Products
- Liposarcoma Assessment by Route of Administration
- Liposarcoma Assessment by Stage and Route of Administration
- Liposarcoma Assessment by Molecule Type
- Liposarcoma Assessment by Stage and Molecule Type

To order this report: Liposarcoma -Pipeline Insights, 2014
http://www.reportlinker.com/p02278625/-Liposarcoma--Pipeline-Insights-2014.html

__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001


'/>"/>

SOURCE Reportlinker
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Lung Adenocarcinoma-Pipeline Insights, 2014
2. Lung Disease-Pipeline Insights, 2014
3. Liver Transplantation-Pipeline Insights, 2014
4. Liver Fibrosis-Pipeline Insights, 2014
5. Liver Diseases-Pipeline Insights, 2014
6. Liver Cirrhosis-Pipeline Insights, 2014
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 ... Markets has announced the addition of the " ... offering. This ... and provides an updated review, including its applications in ... the total market, which includes three main industries: pharmaceutical ...
(Date:6/24/2016)... BEIJING , June 24, 2016 Dehaier ... or the "Company"), which develops, markets and sells medical ... China , signed a strategic cooperation agreement with ... as "Hongyuan Supply Chain") on June 20, 2016, to ... Under the strategic cooperation agreement, Dehaier will leverage Hongyuan ...
(Date:6/24/2016)... 2016 According to a new ... Pen Needles, Safety Pen Needles), Needle Length (4mm, 5mm, ... Mode of Purchase (Retail, Non-Retail) - Trends & Global ... the market for the forecast period of 2016 to ... Billion by 2021 from USD 1.65 Billion in 2016, ...
Breaking Medicine Technology:
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
(Date:6/24/2016)... ... 2016 , ... The Pulmonary Hypertension Association (PHA) learned during ... two significant new grants to support its work to advance research and patient ... recognizing patients, medical professionals and scientists for their work in fighting pulmonary hypertension ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be ...
(Date:6/24/2016)... ... ... makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair Minimum ... by 2020 and then adjusting it yearly to increase at the same rate as the ... wage floor does not erode again, and make future increases more predictable. , The company ...
(Date:6/24/2016)... ... 24, 2016 , ... EB Medicine presented its first-ever “Issue ... conference in Ponte Vedra Beach, FL. The awards honor the outstanding work of ... and Pediatric Emergency Medicine Practice. , “With this award, we recognize the ...
Breaking Medicine News(10 mins):